生产企业：Nuvalent
NVL-655 (neladalkib) is an orally bioavailable, brain-penetrant anaplastic lymphoma kinase (ALK) inhibitor being investigated for the treatment of non-small cell lung cancer. It has received US FDA breakthrough therapy and orphan drug designations. Subject to FDA approval, it is expected to launch in 2026 with multi-blockbuster potential.
NVL-655 (neladalkib) is an orally bioavailable, brain-penetrant anaplastic lymphoma kinase (ALK) inhibitor being investigated for the treatment of non-small cell lung cancer. It has received US FDA breakthrough therapy and orphan drug designations. Subject to FDA approval, it is expected to launch in 2026 with multi-blockbuster potential.
NVL-655 (neladalkib) is a late-stage, potential best-in-class ALK inhibitor under investigation for the treatment of lung cancer, including non-small cell lung cancer (NSCLC).
共 2 项相关疾病
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
